Issue Archive

Proteasome inhibition has proven to be a successful therapeutic strategy in B-cell malignancies including WM. In this issue of Blood, Roccaro and colleagues report preclinical studies, providing the rationale for clinical investigation of a novel orally available proteasome inhibitor in this disease.¹ 

In this issue of Blood, Schulz and colleagues report promising findings using differential proteomics as a discovery tool to identify functionally important proteins in platelet activation. The authors identify several proteins that change in abundance upon platelet activation. These findings implicate several novel pathomechanisms relevant to platelet activation and identify novel potential therapeutic targets for platelet inhibition.¹ 

In this issue of Blood, Brown and colleagues demonstrate the importance of thymic recovery and T-cell reconstitution in CMV-specific immunity after allogeneic UCB transplantation.